Sign In
Buy LOBEF
$0.0889
+0.0166 (+22.96%)
At Close: Jun 03, 2026
Lobe Sciences Provides Update on L-130 Clinical Program
07:00am, Thursday, 07'th Dec 2023
VANCOUVER, British Columbia--(BUSINESS WIRE)--Lobe Sciences Ltd. (OTCQB: LOBEF) (CSE: LOBE) ("Lobe" or the "Company"), a biopharmaceutical company focused on developing transformative medicines to tre
Lobe Sciences reaches 12-month stability milestone with L-130 oral psilocin compound
08:17am, Tuesday, 05'th Dec 2023
Lobe Sciences Ltd (CSE:LOBE, OTCQB:LOBEF) told investors that it reached a significant breakthrough after its lead clinical asset, L-130, surpassed the 12-month stability milestone with no signs of de
Lobe Sciences Provides Update on L-130 Oral Psilocin Compound
06:30am, Tuesday, 05'th Dec 2023
VANCOUVER, British Columbia--(BUSINESS WIRE)--Lobe Sciences Reports 12 Months Stability for Lead Psilocin Drug Candidate (L-130).
Lobe Sciences appoints Mathew Lee as its next CFO
01:55pm, Monday, 18'th Sep 2023
Lobe Sciences Ltd (CSE:LOBE, OTCQB:LOBED) has announced Mathew Lee as its new Chief Financial Officer. Lee is the president of Manning Lee Management Ltd, a management consulting firm providing CFO se
Lobe Sciences, Ltd. Announces The Appointment Of Mathew Lee As CFO
12:44pm, Monday, 18'th Sep 2023
VANCOUVER, British Columbia--(BUSINESS WIRE)--Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company"), a North American Biopharmaceutical Company committed to discovering and developin
Lobe Sciences announces amendment to Altemia acquisition agreement
08:16am, Friday, 15'th Sep 2023
Lobe Sciences Ltd (CSE:LOBE, OTCQB:LOBED) told investors that it signed an amendment to its April 18, 2023, share purchase agreement to acquire Altemia & Company LLC. The deal includes all of Altemia'
Lobe Sciences, Ltd. Announces Amendment to the Acquisition of Altemia™ & Company
06:00pm, Thursday, 14'th Sep 2023
VANCOUVER, British Columbia--(BUSINESS WIRE)--Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company"), a North American Biopharmaceutical Company committed to discovering and developin
Lobe Sciences provides further details regarding Altemia acquisition
08:17am, Monday, 03'rd Jul 2023
Lobe Sciences Ltd (CSE:LOBE, OTCQB:LOBED) has provided further details regarding its acquisition of Altemia & Company LLC, first announced on April 18, 2023, following a review by the British Columb
Lobe Sciences commences Phase 1 clinical study to evaluate L-130
08:16am, Tuesday, 27'th Jun 2023
Lobe Sciences Ltd (CSE:LOBE, OTCQB:LOBED) said it has commenced a Phase 1 clinical study to evaluate L-130, their proprietary stabilized psilocin analogue drug candidate. The trial aims to determine t
Lobe Sciences appoints Baxter Phillips III as chief operating officer
08:16am, Wednesday, 07'th Jun 2023
Lobe Sciences Ltd (CSE:LOBE, OTCQB:LOBED) said it has appointed Baxter Phillips III to the newly created position of chief operating officer (COO) effective immediately. Phillips will also serve as pr
Lobe Sciences names Pentec Health as exclusive US distributor of medical food Altemia for sickle cell disease
10:03am, Wednesday, 17'th May 2023
Lobe Sciences said it has entered into a commercial distribution agreement with Pentec Health for Altemia, a medical food with Lobe's proprietary formulation of emulsified docosahexaenoic acid ethyl e
Lobe Sciences stock flies after its new acquisition spells revenue
01:16pm, Tuesday, 18'th Apr 2023
Lobe Sciences Ltd (CSE:LOBE, OTCQB:LOBED) stock shot up Tuesday after the biopharma company said it had inked a share purchase agreement to acquire Altemia & Company LLC to boost its rare disease port
Lobe Sciences boosts rare disease drug development portfolio with $3.8M acquisition
10:43am, Tuesday, 18'th Apr 2023
Lobe Sciences Ltd (CSE:LOBE, OTCQB:LOBED) revealed that it has inked a share purchase agreement to acquire Altemia & Company LLC and all its assets, intellectual property and inventory to manage patie
Lobe Sciences to Present at Sequire Cannabis & Psychedelics Conference April 5, 2023
08:00am, Tuesday, 04'th Apr 2023
Vancouver, British Columbia--(Newsfile Corp. - April 4, 2023) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company") a North American Biopharmaceutical company committed to disco
Lobe Sciences partner gets DEA quota to produce psilocin drug for two studies
11:01am, Wednesday, 22'nd Mar 2023
Lobe Sciences Ltd (CSE:LOBE, OTCQB:LOBED) announced that its exclusive commercial manufacturing partner has received an initial 2023 quota for the company's novel psilocin drug product (L-130) from th
